Cheapest Ways to Get GLP-1 Drugs: Every Access Pathway Ranked by Cost

The cost problem and why it matters

GLP-1 drugs produce the most significant pharmacological weight loss ever demonstrated. They also cost $1,000–$1,350/month at list price in the United States.

The majority of American adults with obesity who would benefit medically do not have insurance that covers these drugs. Medicare did not cover anti-obesity drugs at all until 2026 (IRA provisions). Many commercial plans still exclude obesity medications. The result: effective drugs that are unaffordable for most people who need them.

This article covers every legitimate access pathway, ranked from lowest to highest cost.

Option 1: FDA-approved drug via manufacturer savings programme

How it works: Novo Nordisk (NovoCare) and Eli Lilly (LillyDirect) run manufacturer savings programmes that substantially reduce out-of-pocket costs for qualifying patients.

NovoCare Wegovy Savings Offer

• Eligible: Commercially-insured patients with a Wegovy prescription; also income-limited uninsured patients through the patient assistance programme
• Cost: As low as $0/month for commercially insured, $499/month for those without adequate coverage
• Enrolment: Via NovoCare website or your prescriber

LillyDirect Zepbound Access

• Similar structure to NovoCare
• Cost: Approximately $550/month for qualifying patients
• Enrolment: LillyDirect website

Medicare Part D patients: The Inflation Reduction Act authorised Medicare Part D coverage of anti-obesity drugs for the first time. Coverage implementation is phased through 2026. Check with your specific Part D plan for current formulary status.

Best for: Patients with commercial insurance who face high copays or deductibles; income-limited patients who qualify for patient assistance.

Option 2: Insurance coverage (prior authorisation)

How it works: Many commercial insurance plans cover Wegovy, Zepbound, Ozempic, or Mounjaro — often requiring prior authorisation. The copay with insurance is typically $25–75/month for the approved brand.

The challenge: Coverage for obesity-indication drugs (Wegovy, Zepbound) is less standardised than T2D-indication drugs (Ozempic, Mounjaro). Approximately 40–50% of commercial plans now cover obesity drugs; the rest do not.

What to check:

1. Call your insurance and specifically ask whether Wegovy (or Zepbound) is on your formulary
2. If yes: ask what tier (copay varies by tier) and what prior authorisation documents are required
3. If no: ask about Ozempic (if you have T2D) or whether the plan covers any GLP-1 drug for obesity

Timeline: Prior authorisation typically takes 1–4 weeks. Appeals of denials often succeed — see our prior authorisation appeal guide.

Best for: Patients with insurance who are willing to invest time in the prior authorisation and appeal process.

Option 3: Compounded semaglutide from a reputable pharmacy

How it works: §503A compounding pharmacies prepare semaglutide for individual patients at substantially lower cost than branded versions. See our article on compounded vs brand semaglutide for the regulatory context.

Cost: $150–$350/month depending on provider and dose. Common pricing:

• 0.25 mg starter: $150–$200/month
• 1 mg standard dose: $200–$250/month
• 2.4 mg maintenance: $250–$350/month

Provider examples: Many telehealth platforms (Henry Meds, Mochi Health, and similar) supply compounded semaglutide as their primary product.

Caveats:

• Not FDA-approved manufacturing
• The legal basis for 503A compounding changed in early 2025 (shortage designation lifted)
• Quality varies — use PCAB-accredited pharmacies with available COA
• Check for free-base (not salt) formulation

Best for: Patients who cannot access branded drugs and are comfortable with the regulatory context and quality tradeoffs.

Option 4: Compounded tirzepatide from a reputable pharmacy

How it works: Same framework as compounded semaglutide but for tirzepatide.

Cost: $299–$449/month depending on dose and provider.

Additional caveats versus compounded semaglutide:

• More expensive than compounded semaglutide
• The salt-vs-free-base quality issue is a more prominent concern for tirzepatide
• Eli Lilly litigation against compounders creates supply instability risk

Best for: Patients who want tirzepatide's efficacy advantage and cannot afford branded Zepbound, and who are comfortable with the quality and regulatory context.

Option 5: Mark Cuban Cost Plus Drugs / GoodRx + cash-pay pharmacy

How it works: Mark Cuban's Cost Plus Drugs (costplusdrugs.com) negotiates pharmaceutical prices directly. GoodRx aggregates pharmacy discounts.

Current GLP-1 availability at Cost Plus Drugs: Ozempic and Wegovy are not listed at cost-plus pricing as of early 2026 (they have not been added to the formulary). GoodRx provides discounts at participating pharmacies — for some patients in some markets, GoodRx pricing on Ozempic can be $700–$900/month, which is below list price but not dramatically so.

Best for: Checking these platforms is always worthwhile; availability and pricing update regularly.

Option 6: Clinical trials

How it works: Pharmaceutical companies run Phase 2–4 clinical trials of GLP-1 drugs and related compounds. Trial participation provides the study drug free of charge, plus study visits.

Finding trials: ClinicalTrials.gov lists all registered US trials. Search for "semaglutide," "tirzepatide," "GLP-1," "obesity," or specific conditions (sleep apnoea, heart failure, Alzheimer's) to find actively recruiting studies.

What to expect:

• Randomised assignment — you may receive placebo, not drug
• Trial protocol requirements (frequent clinic visits, dietary/activity monitoring)
• Potential exclusion criteria (comorbidities, current medications)
• Typically no cost for study drug; sometimes travel reimbursement

Best for: Motivated patients who meet eligibility criteria and are interested in contributing to research. Not suitable for patients who need immediate access or cannot commit to trial obligations.

Option 7: Prescription in another country

How it works: Several countries have substantially lower GLP-1 prices than the United States. Patients who travel internationally (or have access to healthcare in other countries) sometimes obtain prescriptions there.

Price examples:

• Mexico: Ozempic approximately $200–$300/month (varies by region)
• Canada: Ozempic/Wegovy approximately $200–$400 CAD/month (varies by province)
• UK (private): Mounjaro approximately £130–180/month

Legal and practical considerations:

• Importing prescription drugs into the US for personal use is technically restricted but generally not prosecuted for small personal quantities (FDA enforcement discretion)
• Drug quality standards in Mexico vary; Canadian and European standards are generally equivalent to US FDA
• Requires an in-person or teleconsult prescription from a licensed physician in that country
• Cold-chain shipping (refrigerated) is required; pen delivery in luggage is the most practical method for travellers

Best for: Patients who travel or have international connections and can practically access care. Not a practical primary strategy for most patients.

Choosing the right pathway

Summary

The cheapest legitimate GLP-1 access pathway is insurance coverage at $25–75/month copay — but this requires prior authorisation and not all plans cover obesity drugs. The most accessible low-cost alternative for uninsured patients is compounded semaglutide at $150–$300/month from PCAB-accredited pharmacies. Manufacturer savings programmes (NovoCare/LillyDirect) can bring costs down to $499–$550/month for patients without insurance. Clinical trials offer free drug but require research commitment and tolerating placebo assignment probability. For context on supply disruptions that can affect access to any of these pathways, see GLP-1 drug shortage guide. Patients who need savings card help should also review the GLP-1 savings card guide.